2seventy bio to Participate in Upcoming Investor Conferences

Rhea-AI Summary

2seventy bio, Inc. (NASDAQ: TSVT), a leader in immuno-oncology cell therapy, announced the participation of its management team in two upcoming investor conferences. The conferences are the 17th Annual Citi BioPharma Conference on September 7, 2022, in Boston, and the 2022 Morgan Stanley Global Healthcare Conference on September 14, 2022, in New York. Live webcasts will be available on the company’s website, with replays archived for 30 days. 2seventy bio focuses on developing innovative therapies for cancer treatment.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- 2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, announced today that members of the management team will participate in the following upcoming investor conferences:

• 17th Annual Citi BioPharma Conference, “Cell Therapy Part 1” panel on Wednesday, September 7, 2022 at 9:40am ET in Boston, MA
• 2022 Morgan Stanley Global Healthcare Conference, fireside chat on Wednesday, September 14, 2022 at 11:45am ET in New York, NY

Live webcasts will be available via the Investors and Media section of 2seventy bio’s website at https://ir.2seventybio.com/. A replay will be archived on 2seventy bio’s site for 30 days following the event.

About 2seventy bio
Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. We are building the leading immuno-oncology cell therapy company, focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape.

With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver next generation cellular therapies that focus on a broad range of hematologic malignancies, including the first FDA-approved CAR T cell therapy for multiple myeloma, as well as solid tumors. Our research and development is focused on delivering therapies that are designed with the goal to “think” smarter and faster than the disease. Importantly, we remain focused on accomplishing these goals by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day.

For more information, visit www.2seventybio.com.

Follow 2seventy bio on social media: Twitter and LinkedIn.

2seventy bio is a trademark of 2seventy bio, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005003/en/

Investors:

Jenn Snyder, 617-448-0281

jenn.snyder@2seventybio.com

Media:

Morgan Adams, 774-313-9852

morgan.adams@2seventybio.com

Source: 2seventy bio, Inc.

FAQ

What investor conferences is 2seventy bio participating in September 2022?

2seventy bio will participate in the 17th Annual Citi BioPharma Conference on September 7, 2022, and the Morgan Stanley Global Healthcare Conference on September 14, 2022.

Where can I watch the live webcasts for 2seventy bio's investor conferences?

Live webcasts for 2seventy bio's investor conferences can be viewed on the company's website at https://ir.2seventybio.com/.

What is the stock symbol for 2seventy bio?

The stock symbol for 2seventy bio is TSVT.

What is the focus of 2seventy bio's research and development?

2seventy bio focuses on discovering and developing immuno-oncology cell therapies for a range of cancers, including hematologic malignancies.

How fast is 2seventy bio developing its therapies?

2seventy bio aims to develop therapies at the speed of 270 miles per hour, reflecting their commitment to providing time for patients.